This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pfizer Rises As Analyst Expects Dividend Increase

NEW YORK (AP) ¿ Shares of Pfizer Inc. rose Wednesday after a Credit Suisse analyst said the world's largest drugmaker is likely to raise its dividend up to 20 percent later this month, less than a year after slashing its payout.

Analyst Catherine Arnold said it's likely Pfizer will raise its dividend to 18.5 cents from 16 cents, the start of a series of dividend increases over the next few years.

She said the decision could come as soon as Monday.

In morning trading, Pfizer shares picked up 39 cents, or 2.2 percent, to $18.15.

In January, the New York company halved its quarterly dividend to 16 cents as it needed to pay for its $68 billion purchase of rival Wyeth.

Arnold said a dividend increase to about 18.5 cents or 19.25 cents ¿ 74 to 77 cents for the full year ¿ would please most investors. She added that Wall Street expectations for Pfizer's drug pipeline are very low even though it will report late-stage clinical trial results for three drugs in 2010, with others due the following year. She said those could boost its stock.

Pfizer will report trial data for its Prevnar 13 children's vaccine, its chronic pain drug tanezumab, and Alzheimer's disease drug Dimebon next year, she said.

Pfizer did not immediately return calls seeking comment.
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PFE $33.43 -0.42%
AAPL $92.07 -1.30%
FB $119.11 1.10%
GOOG $708.84 1.10%
TSLA $214.91 1.60%


Chart of I:DJI
DOW 17,686.22 +25.51 0.14%
S&P 500 2,050.14 -0.49 -0.02%
NASDAQ 4,710.2950 -6.7990 -0.14%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs